Xingsheng Hu

1.8k total citations
100 papers, 1.0k citations indexed

About

Xingsheng Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Xingsheng Hu has authored 100 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 71 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Xingsheng Hu's work include Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Research Studies (45 papers) and Lung Cancer Diagnosis and Treatment (20 papers). Xingsheng Hu is often cited by papers focused on Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Research Studies (45 papers) and Lung Cancer Diagnosis and Treatment (20 papers). Xingsheng Hu collaborates with scholars based in China, United States and India. Xingsheng Hu's co-authors include Xuezhi Hao, Yan Wang, Yuankai Shi, Junling Li, Puyuan Xing, Xiaohong Han, Yutao Liu, Hongyu Wang, Sheng Yang and Lin Lin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Xingsheng Hu

96 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xingsheng Hu China	18	635	602	285	182	174	100	1.0k
Ilaria Attili Italy	22	881 1.4×	716 1.2×	321 1.1×	266 1.5×	128 0.7×	66	1.3k
Tetsuhiko Taira Japan	20	589 0.9×	636 1.1×	188 0.7×	203 1.1×	126 0.7×	58	1.1k
Neil J. Shah United States	14	444 0.7×	423 0.7×	241 0.8×	160 0.9×	79 0.5×	83	792
Ettore D’Argento Italy	18	538 0.8×	382 0.6×	218 0.8×	160 0.9×	90 0.5×	52	890
Aija Knuuttila Finland	23	379 0.6×	668 1.1×	217 0.8×	199 1.1×	104 0.6×	54	1.0k
Kazushige Wakuda Japan	24	1.1k 1.7×	1.0k 1.7×	207 0.7×	182 1.0×	224 1.3×	117	1.6k
Sheena Bhalla United States	8	775 1.2×	327 0.5×	301 1.1×	144 0.8×	61 0.4×	26	1.3k
Meredith K. Chuk United States	14	429 0.7×	260 0.4×	175 0.6×	116 0.6×	105 0.6×	29	858
Naoto Morikawa Japan	13	1.0k 1.6×	737 1.2×	509 1.8×	164 0.9×	167 1.0×	47	1.5k
Shefali Chopra United States	14	324 0.5×	547 0.9×	426 1.5×	278 1.5×	187 1.1×	57	1.1k

Countries citing papers authored by Xingsheng Hu

Since Specialization

Citations

This map shows the geographic impact of Xingsheng Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingsheng Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingsheng Hu more than expected).

Fields of papers citing papers by Xingsheng Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingsheng Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingsheng Hu. The network helps show where Xingsheng Hu may publish in the future.

Co-authorship network of co-authors of Xingsheng Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Xingsheng Hu. A scholar is included among the top collaborators of Xingsheng Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingsheng Hu. Xingsheng Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Mindy, Junling Li, Minglei Zhuo, et al.. (2025). Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial. Thoracic Cancer. 16(15). e70137–e70137. 1 indexed citations

Wang, Ying, Jingying Nong, Mingming Hu, et al.. (2024). Disseminated tumor cells in bone marrow as predictive classifiers for small cell lung cancer patients. SHILAP Revista de lepidopterología. 4(4). 335–345. 1 indexed citations

Lu, Jingyu, et al.. (2024). Proteomic profiling reveals the significance of lipid metabolism in small cell lung cancer recurrence and metastasis. Journal of Translational Medicine. 22(1). 1117–1117. 2 indexed citations

Hu, Xingsheng, Chunhong Hu, Xianling Liu, et al.. (2023). Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel–based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Frontiers in Oncology. 12. 1057646–1057646. 4 indexed citations

Zhao, Jun, Tong Chen, Xingsheng Hu, et al.. (2023). Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance. Thoracic Cancer. 14(10). 873–880. 3 indexed citations

Bi, Nan, Xingsheng Hu, Gulidanna Shayan, et al.. (2023). 30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Multicenter, Randomized, Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 117(2). S56–S57. 1 indexed citations

Luo, Zhiguo, Xin Liu, Xiaoying Zhang, et al.. (2023). 1208MO A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary. Annals of Oncology. 34. S712–S712. 2 indexed citations

Feng, Yu, Yunxia Tao, Haizhu Chen, et al.. (2023). Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis. Thoracic Cancer. 14(25). 2536–2547. 15 indexed citations

Yang, Guangjian, Yi Cai, Junling Li, et al.. (2022). Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China. Frontiers in Pharmacology. 13. 919652–919652. 8 indexed citations

10.

Yang, Guangjian, Haiyan Xu, Yaning Yang, et al.. (2022). Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2). BMC Medicine. 20(1). 277–277. 25 indexed citations

11.

Wang, Shouzheng, Jianming Ying, Yan Wang, et al.. (2021). Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic Cancer. 12(21). 2924–2932. 13 indexed citations

12.

Xu, Ziyi, Li Teng, Xingsheng Hu, et al.. (2021). Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC). Thoracic Cancer. 12(17). 2360–2368. 5 indexed citations

13.

Huang, Li‐Ling, Xingsheng Hu, Yan Wang, et al.. (2021). Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients. Thoracic Cancer. 12(13). 1943–1951. 29 indexed citations

14.

Wang, Shouzheng, Tongji Xie, Xuezhi Hao, et al.. (2021). Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thoracic Cancer. 12(19). 2585–2593. 32 indexed citations

15.

Mu, Yuxin, Xuezhi Hao, Puyuan Xing, et al.. (2020). Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Journal of Cancer Research and Clinical Oncology. 146(9). 2427–2433. 53 indexed citations

16.

Ai, Bin, Li Zhang, Dingzhi Huang, et al.. (2020). Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first‐line chemotherapy: A multicenter prospective cohort study. Thoracic Cancer. 11(12). 3641–3644. 4 indexed citations

17.

Hu, Xingsheng, et al.. (2019). Surgery or radiotherapy, which is more effective for upper esophageal carcinoma? A retrospective cohort study based on 191 cases. Iranian Journal of radiation research. 17(4). 595–603. 1 indexed citations

18.

Yang, Lu, Sheng Yang, Yutao Liu, et al.. (2018). Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial. Thoracic Cancer. 9(6). 693–698. 4 indexed citations

19.

Wen, Ya & Xingsheng Hu. (2016). Anti-tumor activity of dendritic cell-cytokine induced killer cells (DC-CIKs) sensitized to HER2 against HER-positive breast cancer cells. Genetics and Molecular Research. 15(2). 2 indexed citations

20.

Mo, Hongnan, Xuezhi Hao, Yutao Liu, et al.. (2016). A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients. Cancer Medicine. 5(6). 1116–1124. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact